« Previous
Next »
Titles
- Compliance policy for certain compounding of oral oxitriptan (5-HTP) drug products for patients with tetrahydrobiopterin (BH4) deficiency: immediately in effect guidance for industry1
- Compliance policy for required warning statements on small-packaged cigars1
- Drug-free community support program: agencies have strengthened collaboration but could enhance grantee compliance and performance monitoring : report to Congressional committees1
- Entities generally met Federal Select Agent Program internal inspection requirements, but CDC could do more to improve effectiveness1
- Extension of certain tobacco product compliance deadlines related to the final deeming rule: (revised)1
- Generic Drug User Fee Amendments of 2012: questions and answers related to self-identification of facilities, review of generic drug submissions, and inspections and compliance1
- Interpretation of and compliance policy for certain label requirement: applicability of certain Federal Food, Drug, and Cosmetic Act requirements to vape shops1
- Laser products: conformance with IEC 60825-1 Ed. 3 and IEC 60601-2-22 Ed. 3.1 : (Laser Notice No. 56) : guidance for industry and Food and Drug Administration staff1
- Medical x-ray imaging devices conformance: guidance for industry and Food and Drug Administration staff1
- OHRP generally conducted its compliance activities independently, but changes would strengthen its independence1
- Optimal use of antibiotics for urinary tract infections in long-term care facilities: successful strategies prevent resident harm1
- Wholesale distributor verification requirement for saleable returned drug product: compliance policy1